February 7 - 10, 2009
Hyatt Regency Boston
Boston, Massachusetts
CHAIRPERSONS:
Lynda Chin, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA
William R. Sellers, Novartis Institute for BioMedical Research, Inc., Cambridge, MA
Richard L. Schilsky, University of Chicago Medical Center, Chicago, IL
In the era of the cancer genome projects, vast and complex epi/genomic and proteomic information annotated with clinical parameters will be generated. How does the cancer research field rapidly convert these data into meaningful functional/mechanistic insights that can advance our understanding of cancer pathogenesis and enable development of new diagnostic and therapeutic agents? Are significant statistical correlations sufficient to harness the full clinical potential of these complex data sets in a manner that will change the practice of cancer medicine? Who will be the "users" of these data? It is envisioned that translation of these data will require multi-disciplinary integrated systems biology approaches not typical of traditional basic and translational research. This meeting is intended to bring together these "users," representing computational biologists, cancer biologists and clinicians who together hold the potential to convert these vast multi-dimensional genomic datasets into basic and translational hypotheses that can be tested and validated, and ultimately use to guide discovery of more effective diagnostic, drugs and associated biomarkers. Emphasis will be on "functionalizing" the genomic insights, development of in vitro and in vivo high-content biological systems that offer a more productive and better defined path to identify and distinguish key pathogenetic events from noise, to assess the diagnostic, prognostic or predictive significance of genomic changes, and to design effective experiments to retrospectively and prospectively validate genomic-based molecular biomarkers and therapeutic targets.
Additional conference information, including information on registration and abstract submission, will be available in August.
Program as of August 25, 2008
| SATURDAY, FEBRUARY 7 |
CONCURRENT EDUCATION SESSIONS
2:00 p.m.-4:15 p.m.
- EDUCATION SESSION 1: CANCER BIOLOGY AND CANCER MEDICINE: A PRIMER FOR GENOMIC SCIENTISTS
What Makes Cancer So Difficult to Treat?
Ronald A. DePinho, Dana-Farber Cancer Institute, Boston, MA
Cancer Evaluation and Treatment in the Genomic Era
Richard L. Schilsky, University of Chicago Medical Center, Chicago, IL
- EDUCATION SESSION 2: BIOSTATISTICS AND CANCER GENOMICS: A PRIMER FOR BIOLOGISTS
Introduction to Basic Tools for Analysis of Genomic Data
John Q. Quackenbush, Dana-Farber Cancer Institute, Boston, MA
Applications to Cancer Genomics
John Q. Quackenbush
|
WELCOME AND OPENING KEYNOTE ADDRESS
6:00 p.m.–7:00 p.m.
Welcome
Patterns of Somatic Mutation in Human Cancer Genomes
Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
|
SESSION 1: CHALLENGES AND OPPORTUNITIES
Chairperson to be announced
7:00 p.m.-9:00 p.m.
Going Beyond p Values
Lynda Chin, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
Omics and Predictive Biomarkers
Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA
Omics in Drug Development
William R. Sellers, Novartis Institute for BioMedical Research, Inc., Cambridge, MA
Biomarkers in the Practice of Medicine
Richard L. Schilsky, University of Chicago Medical Center, Chicago, IL
|
OPENING RECEPTION
9:00 p.m.-10:30 p.m.
|
| SUNDAY, FEBRUARY 8 |
KEYNOTE ADDRESS II
8:15 a.m.-9:00 a.m.
Recurrent Gene Fusions in Prostate Cancer: A New Class of Biomarkers and Therapeutic Targets
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI
|
SESSION 2: CONVERTING DATA INTO HYPOTHESES
Chairperson: John Q. Quackenbush, Dana-Farber Cancer Institute, Boston, MA
9:00 a.m.-11:00 a.m.
Knowledge-Based Methods for Cancer Genomics Studies
Jill P. Mesirov, Broad Institute, Cambridge, MA
Converting Genomic Data into Hypotheses
Cameron W. Brennan, Memorial Sloan-Kettering Cancer Center, New York, NY
Stochasticity and Networks in Genomic Data
John Q. Quackenbush
|
SESSION 3: HIGH THROUGHPUT BIOLOGY: IN VITRO FUNCTIONAL GENETIC SCREEN
Chairperson: Joan S. Brugge, Harvard Medical School, Boston, MA
12:30 p.m.-2:00 p.m.
Genome-scale Cancer Biology with RNAi Cell Arrays
Olli-P. Kallioniemi, VTT Technical Research Center of Finland, Turku, Finland
Functional Genomics, Experimental Models and Cancer
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA
Additional speaker to be announced
Short talks from proffered abstracts
|
SESSION 4: HIGH THROUGHPUT BIOLOGY: IN VIVO FORWARD GENETIC SCREEN
Chairperson: James R. Downing, St. Jude Children's Research Hospital, Memphis, TN
3:00 p.m.-5:00 p.m.
Identification of Tumor Suppressor Genes in vivo Using RNA Interference
Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
A Conditional Transposon-based Insertional Mutagenesis System for Modeling Cancer in Mice
Nancy A. Jenkins, Institute of Molecular and Cell Biology, Singapore
Use of Zebrafish Models and Human Oncogenomics to Find New Cancer Pathways
Leonard I. Zon, Harvard Medical School, Children's Hospital, Boston, MA
Short talks from proffered abstracts
|
POSTER SESSION A / EXHIBITS
7:00 p.m.-9:30 p.m.
|
| MONDAY, FEBRUARY 9 |
SESSION 5: MODEL SYSTEMS FOR COMPARATIVE OMICS
Chairperson: Michael R. Stratton, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom
8:00 a.m.-10:00 a.m.
Integrated Pipeline for Mass Spectrometry-Based Discovery and Confirmation of Biomarkers Demonstrated in a Mouse Model of Breast Cancer
Amanda G. Paulovich, Fred Hutchinson Cancer Research Center, Seattle, WA
Three-Dimensional Cell Culture Models of Cancer
Joan S. Brugge, Harvard Medical School, Boston, MA
Modeling and Mining Cancer Chromosomes and Transcriptomes
Ronald A. DePinho, Dana-Farber Cancer Institute, Boston, MA
Short talks from proffered abstracts
|
SESSION 6: PRECLINICAL THERAPEUTICS
Chairperson: Barbara L. Weber, GlaxoSmithKline, King of Prussia, PA
10:30 a.m.-12:00 p.m.
Oncogenomics to Target Myeloma Cells in the Bone Marrow Milieu
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA
Stress Targeted Cancer Drugs: Preclinical Studies to Help Find the Right Patients
Garth Powis, UT M. D. Anderson Cancer Center, Houston, TX
How to Define a Cancer Drug Target
Edward A. Sausville, University of Maryland, Baltimore, MD
|
POSTER SESSION B / EXHIBITS
1:00 p.m.-3:30 p.m.
|
SESSION 7: TRANSLATIONAL MEDICINE
Chairperson: Olli-P. Kallioniemi, VTT Technical Research Center of Finland, Turku, Finland
3:30 p.m.-6:00 p.m.
Discovery of Next Generation Drug Targets and Response Markers from Human Gene Expression Data
Lajos Pusztai, UT M. D. Anderson Cancer Center, Houston, TX
Tracking Genomic Alterations in Individuals with Cancer
David Sidransky, Johns Hopkins Medical Institute, Baltimore, MD
Genomic Strategies for Personalized Cancer Therapy
Joseph R. Nevins, Duke University, Durham, NC
Genomic Approaches to Targeted Drug Development
Barbara L. Weber, GlaxoSmithKline, King of Prussia, PA
|
KEYNOTE ADDRESS III
6:00 p.m.-6:45 p.m.
Molecular Genetics of Acute Leukemia
James R. Downing, St. Jude Children's Research Hospital, Memphis, TN
|
CLOSING REMARKS
6:45 p.m.-7:00 p.m.
|
DEPARTURE |